Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

ESMO open·2026

Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026

Same author

Radiotherapy Plan Quality Assurance in the ABC-07 Trial of Stereotactic Body Radiotherapy for Locally Advanced Biliary Tract Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026

Same author

Establishing a National SABR Service: A Model for Safe and Effective Clinical Implementation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

Same author

Reconsidering Governance Models to Strengthen Rural Healthcare.

Journal of bioethical inquiry·2025

Same author

Liver Metastases Treated With Magnetic Resonance Imaging Guided Stereotactic Body Radiation Therapy: Outcomes of Tolerability, Acute Toxicity, and Quality of Life From the MOMENTUM Study.

Practical radiation oncology·2025

Search research articles

Related Experiment Video

Updated: Jul 26, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.

G G Hanna¹, L Murray², R Patel³

¹Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))

|October 17, 2017

Summary

Six UK studies on stereotactic ablative radiotherapy (SABR) for oligometastatic disease have established consensus organ at risk dose constraints. This unified approach aims to standardize SABR implementation and enable robust toxicity comparisons internationally.

Keywords:

Constraints OAR SABR SBRT normal tissue stereotactic radiotherapy

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Jul 26, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Oncology
Radiation Oncology
Medical Physics

Background:

Stereotactic ablative radiotherapy (SABR) is increasingly used for oligometastatic disease.
Several UK-based clinical trials investigating SABR are currently active.
Standardized organ at risk (OAR) dose constraints are crucial for safe and comparable SABR implementation.

Purpose of the Study:

To develop a consensus document on OAR dose constraints for SABR studies in the UK.
To update existing dose constraints using data from current UK SABR trials.
To facilitate standardized SABR implementation and facilitate international toxicity comparisons.

Main Methods:

Collaboration among members of multiple SABR trial management groups.
Review and update of existing OAR dose constraints.
Utilizing data from six ongoing UK SABR studies.

Main Results:

A consensus document on appropriate OAR dose constraints for SABR has been generated.
Updated dose constraints incorporate data from current UK SABR studies.
The consensus provides a unified approach for SABR implementation.

Conclusions:

The developed consensus document will promote standardized SABR practices across the UK.
This unified approach is expected to improve the comparability of toxicity data between SABR studies, both nationally and internationally.